State & Local Municipalities
Rebel Distributors has developed repackaging, relabeling, and stockpiling programs that benefit state and local government municipalities. Our most popular programs include relabeling Tamiflu® and Relenza® and repackaging Doxycycline and Ciprofloxacin for government agencies and their respective stockpiling programs. We can provide any product in customized sizes and quantities and meet any label formatting requirements. Additionally we can supply bulk pharmaceuticals to any state or local clinic or agency.
For more information relating to state & local municipalities, email us at info@rebelrx.com.
First Responders
When a biological emergency occurs, it is critical for your First Response team to have immediate access to medications to ensure their health and the safety of others. Since the CDC will not be contacted until Federal and Local authorities agree the SNS is needed, and because the CDC has specifically stated, “The SNS is not a first response tool,” city, county, and state agencies must make the necessary preparations to ensure these medications are readily available at all times. With the help of Rebel Distributors First Response Program you can assure the immediate treatment for your First Responders is available when a catastrophe occurs.
For more information relating to first responders, email us at info@rebelrx.com.
340B
The 340B Drug Pricing Program resulted from enactment of Public Law 102-585, the Veterans Health Care Act of 1992, which is codified as Section 340B of the Public Health Service Act. Section 340B limits the cost of covered outpatient drugs to certain federal grantees, federally-qualified health center look-alikes and qualified hospitals. The purpose of the 340B Program is to enable these entities to stretch scarce federal resources, reaching more eligible patients and providing more comprehensive services. Rebel Distributors is committed to offering cost effective prepackaged medications to 340B clinics and enable them to reduce the handling and dispensing costs associated with managing their bulk pharmaceutical products.
For more information relating to 340B, email us at info@rebelrx.com.